Literature DB >> 27510552

Identifying protein aggregation mechanisms and quantifying aggregation rates from combined monomer depletion and continuous scattering.

Gregory V Barnett1, Michael Drenski2, Vladimir Razinkov3, Wayne F Reed4, Christopher J Roberts5.   

Abstract

Parallel temperature initial rates (PTIR) from chromatographic separation of aggregating protein solutions are combined with continuous simultaneous multiple sample light scattering (SMSLS) to make quantitative deductions about protein aggregation kinetics and mechanisms. PTIR determines the rates at which initially monomeric proteins are converted to aggregates over a range of temperatures, under initial-rate conditions. Using SMSLS for the same set of conditions provides time courses of the absolute Rayleigh scattering ratio, IR(t), from which a potentially different measure of aggregation rates can be quantified. The present report compares these measures of aggregation rates across a range of solution conditions that result in different aggregation mechanisms for anti-streptavidin (AS) immunoglobulin gamma-1 (IgG1). The results illustrate how the two methods provide complementary information when deducing aggregation mechanisms, as well as cases where they provide new mechanistic details that were not possible to deduce in previous work. Criteria are presented for when the two techniques are expected to give equivalent results for quantitative rates, the potential limitations when solution non-idealities are large, as well as a comparison of the temperature dependence of AS-IgG1 aggregation rates with published data for other antibodies.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aggregation mechanisms; Aggregation rates; Laser scattering; Protein stability

Mesh:

Substances:

Year:  2016        PMID: 27510552      PMCID: PMC5004974          DOI: 10.1016/j.ab.2016.08.002

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  43 in total

1.  Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies.

Authors:  Douglas D Banks; Ramil F Latypov; Randal R Ketchem; Jon Woodard; Joanna L Scavezze; Christine C Siska; Vladimir I Razinkov
Journal:  J Pharm Sci       Date:  2012-05-30       Impact factor: 3.534

2.  Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms.

Authors:  Rebecca K Brummitt; Douglas P Nesta; Liuquan Chang; Andrew M Kroetsch; Christopher J Roberts
Journal:  J Pharm Sci       Date:  2011-01-06       Impact factor: 3.534

Review 3.  Antibody structure, instability, and formulation.

Authors:  Wei Wang; Satish Singh; David L Zeng; Kevin King; Sandeep Nema
Journal:  J Pharm Sci       Date:  2007-01       Impact factor: 3.534

4.  Population balance modeling of antibodies aggregation kinetics.

Authors:  Paolo Arosio; Simonetta Rima; Marco Lattuada; Massimo Morbidelli
Journal:  J Phys Chem B       Date:  2012-06-04       Impact factor: 2.991

Review 5.  Protein aggregation: folding aggregates, inclusion bodies and amyloid.

Authors:  A L Fink
Journal:  Fold Des       Date:  1998

6.  Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates.

Authors:  Paolo Arosio; Simonetta Rima; Massimo Morbidelli
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

7.  Monitoring protein aggregation kinetics with simultaneous multiple sample light scattering.

Authors:  Michael F Drenski; Mark L Brader; Roy W Alston; Wayne F Reed
Journal:  Anal Biochem       Date:  2013-03-07       Impact factor: 3.365

Review 8.  Therapeutic protein aggregation: mechanisms, design, and control.

Authors:  Christopher J Roberts
Journal:  Trends Biotechnol       Date:  2014-06-04       Impact factor: 19.536

9.  Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life.

Authors:  Christopher J Roberts; Richard T Darrington; Maureen B Whitley
Journal:  J Pharm Sci       Date:  2003-05       Impact factor: 3.534

10.  Protein-protein interactions in dilute to concentrated solutions: α-chymotrypsinogen in acidic conditions.

Authors:  Marco A Blanco; Tatiana Perevozchikova; Vincenzo Martorana; Mauro Manno; Christopher J Roberts
Journal:  J Phys Chem B       Date:  2014-05-21       Impact factor: 2.991

View more
  6 in total

1.  Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification.

Authors:  Weixin Jin; Zizhuo Xing; Yuanli Song; Chao Huang; Xuankuo Xu; Sanchayita Ghose; Zheng Jian Li
Journal:  MAbs       Date:  2019-09-02       Impact factor: 5.857

2.  High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.

Authors:  Mitja Zidar; Ana Šušterič; Miha Ravnik; Drago Kuzman
Journal:  Pharm Res       Date:  2017-06-07       Impact factor: 4.200

3.  Characterizing aggregate growth and morphology of alanine-rich polypeptides as a function of sequence chemistry and solution temperature from scattering, spectroscopy, and microscopy.

Authors:  Bradford Paik; Cesar Calero-Rubio; Jee Young Lee; Xinqiao Jia; Kristi L Kiick; Christopher J Roberts
Journal:  Biophys Chem       Date:  2020-09-25       Impact factor: 2.352

4.  Parallel chromatography and in situ scattering to interrogate competing protein aggregation pathways.

Authors:  Diana Gomes; Rebecca K Kalman; Rebecca K Pagels; Miguel A Rodrigues; Christopher J Roberts
Journal:  Protein Sci       Date:  2018-06-13       Impact factor: 6.725

5.  Surfaces Affect Screening Reliability in Formulation Development of Biologics.

Authors:  Mitja Zidar; Gregor Posnjak; Igor Muševič; Miha Ravnik; Drago Kuzman
Journal:  Pharm Res       Date:  2020-01-06       Impact factor: 4.200

Review 6.  Protein aggregation and immunogenicity of biotherapeutics.

Authors:  Ngoc B Pham; Wilson S Meng
Journal:  Int J Pharm       Date:  2020-06-09       Impact factor: 5.875

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.